Drug Profile


Alternative Names: 116 258; Jevtana; RPR 116258; RPR 116258A; Taxoid-116258; TXD 258; XRP6258

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell and embryonal neoplasms; Liposarcoma; Penile cancer; Small cell lung cancer; Urogenital cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer; Head and neck cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Second-line therapy or greater) in South Korea (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(First-line therapy, Late-stage disease) in USA (IV, Infusion)
  • 12 Sep 2017 Sanofi terminates the phase III SENSI-CAB trial due to low inclusion rate in Prostate cancer (Combination therapy, Metastatic disease, First-line therapy) in Sweden (IV) (NCT01978873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top